MVRIX Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $5.73M

  • Investors
  • 9

MVRIX General Information

Description

Operator of a biotechnology company intended for biologics discovery and development. The company develops new drugs based on platform technology related to membranes and viruses, enabling humans to be free from the attack of viruses and microorganisms.

Contact Information

Website
www.mvrix.co.kr
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 513, Building 1, Ace Hitech City Pyeongchon
  • 457-27, Heungan-daero, Dongan-gu, Anyang-si
  • Hwaseong, Gyeonggi-do
  • South Korea
Primary Industry
Biotechnology
Corporate Office
  • Room 513, Building 1, Ace Hitech City Pyeongchon
  • 457-27, Heungan-daero, Dongan-gu, Anyang-si
  • Hwaseong, Gyeonggi-do
  • South Korea

MVRIX Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MVRIX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 04-Sep-2026 $5.73M Completed Clinical Trials - General
2. Early Stage VC (Series A) 13-Mar-2025 Completed Pre-Clinical Trials
1. Seed Round $2.41M $2.41M Completed Pre-Clinical Trials
To view MVRIX’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

MVRIX Patents

MVRIX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026212425-A1 Lipid nanoparticles conjugated with clusterin-fused antibody Pending 31-Mar-2025
WO-2026160580-A1 Recombinant botulinum toxin and pharmaceutical composition containing same Pending 23-Jan-2025
WO-2026010379-A1 Pharmaceutical composition containing her2-binding lipid nanoparticles loaded with mrna encoding p53 protein Pending 02-Jul-2024
WO-2026010380-A1 Pharmaceutical lipid nanoparticle composition with improved targeted delivery ability and safety Pending 02-Jul-2024
EP-4711379-A1 Method for producing botulinum neurotoxin using soluble partner and gp41.1 intein Pending 07-Mar-2024 C12N9/52
To view MVRIX’s complete patent history, request access »

MVRIX Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ajin Industrial Corporation Minority
Interbest Corporation Minority
InterVest Venture Capital Minority
Korea Investment Partners Venture Capital Minority
Korea Omega Investment Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

MVRIX FAQs

  • When was MVRIX founded?

    MVRIX was founded in 2021.

  • Where is MVRIX headquartered?

    MVRIX is headquartered in Hwaseong, South Korea.

  • What industry is MVRIX in?

    MVRIX’s primary industry is Biotechnology.

  • Is MVRIX a private or public company?

    MVRIX is a Private company.

  • What is MVRIX’s current revenue?

    The current revenue for MVRIX is .

  • How much funding has MVRIX raised over time?

    MVRIX has raised $11.6M.

  • Who are MVRIX’s investors?

    Ajin Industrial, Interbest, InterVest, Korea Investment Partners, and Korea Omega Investment are 5 of 9 investors who have invested in MVRIX.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process